Literature DB >> 21871940

Aluminium-based adjuvants should not be used as placebos in clinical trials.

Christopher Exley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871940     DOI: 10.1016/j.vaccine.2011.08.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  8 in total

1.  Zinc Improves Cognitive and Neuronal Dysfunction During Aluminium-Induced Neurodegeneration.

Authors:  Neha Singla; D K Dhawan
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

2.  Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy.

Authors:  Christopher Exley
Journal:  Allergy Asthma Clin Immunol       Date:  2014-01-20       Impact factor: 3.406

Review 3.  Aluminum-induced entropy in biological systems: implications for neurological disease.

Authors:  Christopher A Shaw; Stephanie Seneff; Stephen D Kette; Lucija Tomljenovic; John W Oller; Robert M Davidson
Journal:  J Toxicol       Date:  2014-10-02

Review 4.  Deceptology in cancer and vaccine sciences: Seeds of immune destruction-mini electric shocks in mitochondria: Neuroplasticity-electrobiology of response profiles and increased induced diseases in four generations - A hypothesis.

Authors:  Mahin Khatami
Journal:  Clin Transl Med       Date:  2020-12

5.  Was amorphous aluminium hydroxyphosphate sulfate adequately evaluated before authorisation in Europe?

Authors:  Sesilje B Petersen; Christian Gluud
Journal:  BMJ Evid Based Med       Date:  2020-08-06

6.  Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis.

Authors:  Sara Russo Krauss; Marija Barbateskovic; Sarah Louise Klingenberg; Snezana Djurisic; Sesilje Bondo Petersen; Mette Kenfelt; De Zhao Kong; Janus C Jakobsen; Christian Gluud
Journal:  BMJ Open       Date:  2022-06-23       Impact factor: 3.006

7.  Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil.

Authors:  Rotem Inbar; Ronen Weiss; Lucija Tomljenovic; Maria-Teresa Arango; Yael Deri; Christopher A Shaw; Joab Chapman; Miri Blank; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 4.505

Review 8.  Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action.

Authors:  Emma Shardlow; Matthew Mold; Christopher Exley
Journal:  Allergy Asthma Clin Immunol       Date:  2018-11-07       Impact factor: 3.406

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.